GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (FRA:4FR) » Definitions » Valuation Rank

Faron Pharmaceuticals Oy (FRA:4FR) Valuation Rank


View and export this data going back to 2023. Start your Free Trial

What is Faron Pharmaceuticals Oy Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Faron Pharmaceuticals Oy Valuation Rank Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Faron Pharmaceuticals Oy Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (FRA:4FR) » Definitions » Valuation Rank
Comparable Companies
LSE:4BB LSE:BVXP LSE:AVCT LSE:IBT LSE:HVO LSE:SCLP LSE:OBI LSE:SBTX LSE:FUM LSE:PRTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
FARN:UK FARON:Finland
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Website
https://www.faron.com
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.